Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. (symbol: COCP) is an innovative pharmaceutical company dedicated to discovering and developing novel antiviral therapeutics. With a primary focus on treating serious and chronic viral diseases, Cocrystal employs advanced technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. By leveraging unique nucleoside chemistry and a market-focused approach to drug discovery, the company aims to deliver small molecule therapeutics that are safe, effective, and convenient to administer.
The company has made significant strides in identifying promising preclinical stage antiviral compounds that address unmet medical needs. These include treatments for hepatitis, influenza, and norovirus infections. Among its notable projects, Cocrystal Pharma is developing CC-31244, an oral, broad-spectrum replication inhibitor known as a non-nucleoside inhibitor (NNI). This investigational drug targets the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses, showcasing the company's commitment to creating groundbreaking antiviral solutions.
Cocrystal Pharma has garnered strategic investments from major industry players such as Teva Pharmaceuticals, Opko Health (OPK), Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group. This backing underscores the confidence that leading pharmaceutical entities have in Cocrystal's potential and technological capabilities.
As Cocrystal Pharma continues to advance its pipeline of antiviral therapeutics, the company's innovative approach and robust partnerships position it as a significant player in the biotechnology sector. Investors and stakeholders can stay updated on the latest developments, financial reports, and strategic initiatives that propel Cocrystal Pharma forward in its mission to combat viral diseases.
For those interested in the latest updates and relevant information regarding Cocrystal Pharma and its stock performance, be sure to check the latest news and announcements below.
- ---
- ---
- ---
- ---
- ---
- ---
Cocrystal Pharma, Inc. (COCP) announced the appointment of Fred Hassan to its Board of Directors, expanding the board to six members. Hassan brings over 40 years of experience in the pharmaceutical industry, having held senior roles at major companies and investment firms. His recent $2 million investment in Cocrystal via an at-the-market private placement underscores his confidence in the company's prospects.
The Chairman of the Board, Roger Kornberg, expressed optimism that Hassan's expertise will strengthen corporate governance and help advance Cocrystal's antiviral pipeline. Hassan emphasized the company's potential to develop innovative antiviral therapies using a unique structure-based discovery platform. This announcement signals a strategic move for Cocrystal as it aims to enhance its leadership and drive its research efforts towards commercialization.
Cocrystal Pharma (Nasdaq: COCP) announces the acceptance of an oral presentation of new data from its CC-42344 Phase 1 influenza A study at the 7th Annual ISIRV Antiviral Group Conference on May 4, 2023. Dr. Sam Lee, President and co-CEO, will present insights on the first-in-human study of CC-42344, a novel broad-spectrum influenza A polymerase PB2 inhibitor. The company anticipates filing for regulatory approval for a Phase 2a human challenge study later in 2023. CC-42344 has shown potent antiviral activity against various influenza A strains, including those resistant to existing treatments like Tamiflu and Xofluza.
This presentation aligns with the conference theme, “Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19.” Cocrystal plans to summarize the data presented and share slides on its website after the conference.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced a private placement of 2,030,458 shares of common stock at $1.97 per share, raising $4.0 million. The investment was made by notable industry leaders Phillip Frost, M.D., and Fred Hassan, each contributing $2.0 million. This capital infusion strengthens Cocrystal's financial position as it prepares for significant clinical milestones. The company is set to commence a Phase 2a human challenge study for its PB2 inhibitor CC-42344 and a first-in-human trial for its COVID-19 protease inhibitor CDI-988, both pending regulatory approvals. Additionally, a lead candidate in the norovirus program is expected to be selected by mid-2023.
FAQ
What is the current stock price of Cocrystal Pharma (COCP)?
What is the market cap of Cocrystal Pharma (COCP)?
What does Cocrystal Pharma, Inc. do?
What are Cocrystal Pharma's key areas of focus?
What is CC-31244?
What technologies does Cocrystal employ?
Who are some of Cocrystal Pharma's strategic investors?
How does Cocrystal's drug discovery approach differ from others?
What stage are Cocrystal's antiviral compounds in?
What makes Cocrystal Pharma unique?
Where can I find the latest news on Cocrystal Pharma?
What is the main goal of Cocrystal Pharma?
